secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-020846
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa Q1 net loss $32M; cash $237M; MRT-2359 data on track for H2 2023
---------------------------------------------------------------------------

- Net loss $32M in Q1 2023 vs $23.9M in Q1 2022; R&D expenses $26.8M vs $17.9M.
- Cash, equivalents, and marketable securities $237M as of March 31, 2023, down from $268.1M at Dec 31, 2022; runway into 2025.
- Phase 1/2 trial of MRT-2359 in MYC-driven solid tumors on track for initial data in H2 2023.
- VAV1 program expects to declare a development candidate in Q2 2023.
- Appointed Jan Skvarka, Ph.D., MBA, to the Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017023020846/0000950170-23-020846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017023020846/glue-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer